What is MGF?
MGF can refer to an IGF-1 splice-product context or a synthetic terminal E-peptide. A primary replication study found no apparent effect of the tested MGF peptides on muscle-cell proliferation or differentiation.
Video overview · 3:22
PEG-MGF (Mechano Growth Factor): Does It Build Muscle? What the Research Shows
Where mechano growth factor comes from, the cell studies behind the muscle claim, the two-company replication that found no effect, why PEG-MGF itself has never been studied, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
PEG-MGF is sold online as a muscle-building peptide, and the FDA's compounding panel is due to review it by early 2027. The story behind it starts with a real discovery in stretched muscle. But PEG-MGF itself has never been studied. Here's what's actually known.
In 1996, a London team led by Geoffrey Goldspink found an unusual version of the growth factor IGF-1 in stretched muscle. It was later named mechano growth factor. What's sold online is a short lab-made piece of its tail, about twenty-four amino acids. PEG-MGF is that piece with polyethylene glycol attached, meant to make it last longer.
Here's the idea. Loading a muscle switches on mechano growth factor, which was proposed to wake up muscle stem cells, called satellite cells, so they multiply and help repair. In older rats, muscle made much less of it. Whether a vial of the lab-made piece does any of this in a person has never been tested.
In 2002, the original team reported that the tail piece made muscle cells multiply in a dish. A 2011 study saw longer growth in muscle cells from young donors, but not from older ones. Then, in 2014, scientists at two drug companies tried to repeat the work. The peptide had no effect on mouse or human muscle cells, while ordinary IGF-1 worked in the same tests.
Outside muscle, modified versions of the peptide helped heart function after heart attacks in mice, and helped bone and cartilage repair in rabbits. But those studies used other forms of the peptide, some stabilized differently or released from a scaffold. We found no published study of PEG-MGF itself, in cells, animals or people.
In people, nobody has been given MGF or PEG-MGF in a published or registered trial. The one well-known human study only measured the body's own MGF: after heavy leg exercise, it rose in eight young men, but not in seven older men.
PEG-MGF is not FDA approved. The FDA warns it may carry a significant risk of immune reactions, notes impurity concerns, and says it has found no human exposure data. It's on the agenda for the FDA's next compounding advisory meeting. Anti-doping labs have found mislabeled MGF products, and the World Anti-Doping Agency bans mechano growth factors at all times.
Does PEG-MGF build muscle in people? Unproven: no human trial has given it. Does MGF activate muscle stem cells? Mixed: the original lab says yes, a two-company replication found nothing. Does PEG-MGF work like MGF, only longer? Unknown: it has never been studied. And is it allowed in sport? No.
The bottom line: mechano growth factor is a real form of IGF-1 that muscle makes when it's loaded. But the muscle-building claim rests on cell studies that a careful replication couldn't confirm, PEG-MGF has never been studied, and it isn't approved. For every study and source, see the PEG-MGF profile on PepsRadar dot com.
Biological role or research focus
Muscle-cell signaling and replication findings.
Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.
Names you may encounter
Mechano-growth factor · MGF E-peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- IGF-1 splice-product / E-peptide research label
- Research focus
- Muscle-cell signaling and replication findings
- Featured evidence
- Cell study with negative replication findings
- Source check
- October 4, 2026
Quick answers
- Is MGF FDA approved?
- No. No FDA-approved drug contains MGF. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is MGF safe?
- Unapproved IGF-1 splice fragment with no published human safety studies. A replication study found no clear effect on muscle cells, and risks in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is MGF banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.3 Growth factors and growth factor modulators). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| MGF peptide replication in muscle cells (2014) | Cell study with negative replication findings | C2C12 cells, primary human muscle myoblasts, and primary mouse muscle stem cells. |
Claim check
False What is metatrutide ('GLP-4')? What's actually in the vial
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Cell study with negative replication findings · 2014
MGF peptide replication in muscle cells
What did this publication test, and what did it find?
- Population / model
- C2C12 cells, primary human muscle myoblasts, and primary mouse muscle stem cells.
- Study design
- Laboratory attempts to reproduce proposed proliferation, differentiation, and signaling effects using MGF peptides and IGF-1-related controls.
- Main finding
- MGF did not increase proliferation or inhibit differentiation in the tested systems. IGF-1 and full-length IGF-1Eb produced proliferative responses; tested MGF peptides also failed to demonstrate the proposed signaling response.
- Limits & context
- Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming MGF as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. ↗
Heart, lung & circulation · 2008 Feb · Comparative Study, Journal Article
African swine fever virus MGF_110-3L and MGF_110-4L signal TLR2-mediated lethal inflammation. ↗
Protein & cell · 2026 Jul 14 · Journal Article
Growth factors and muscle ageing. ↗
Experimental gerontology · 2004 Oct · Journal Article, Research Support, Non-U.S. Gov't, Review
Mangiferin: A natural neuroprotective polyphenol with anti-inflammatory and anti-oxidant properties for depression. ↗
Progress in neuro-psychopharmacology & biological psychiatry · 2025 Jun 20 · Journal Article, Review, Research Support, Non-U.S. Gov't
Risks & interactions
Unapproved IGF-1 splice fragment with no published human safety studies. A replication study found no clear effect on muscle cells, and risks in people are unknown.
No published human safety studies were found. Evidence comes from cell and animal experiments, and a careful replication study found tested MGF peptides had no apparent effect on muscle cells. Safety of products sold as MGF is unknown.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: MGF peptide has no apparent effect on myoblasts or muscle stem cells (2014) ↗
Safety & what remains unknown
Cell experiments do not establish systemic safety or a useful human muscle-recovery intervention.
Evidence boundaries
Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 ("Mechano growth factor (MGF)", nominated without adequate support). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.3 Growth factors and growth factor modulators
Named explicitly ("Mechano growth factors (MGFs)"). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile covers unpegylated MGF peptide research. PEG-MGF is a different conjugate whose sequence, polymer, and attachment must be specified.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The study separated a synthetic terminal fragment from mature IGF-1 and full-length IGF-1Eb. A response to the full protein cannot be attributed automatically to the isolated fragment.
Questions worth asking
- Is MGF peptide evidence interchangeable with PEG-MGF or IGF-1 evidence?
- What material, population, and route were actually studied?
- Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is MGF peptide evidence interchangeable with PEG-MGF or IGF-1 evidence?
No. A terminal fragment, a full-length growth factor, and a PEG conjugate are different preparations. The negative fragment findings should remain visible.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
